Zuclopenthixol decanoate injection

- arteriosclerosis, a disease affecting the arteries
- convulsions, fits or seizures
- decreased blood supply to the brain
- diabetes, a disorder of metabolism in which the amount of sugar in the blood is too high
- feeling lethargic, indifferent, lost or remote
- glaucoma, a condition in which there is usually a build-up of pressure in the eye
- heart and blood vessel problems
- kidney problems
- liver problems
- low potassium and/or low magnesium levels in the blood
- organic brain syndrome
- parkinsonism, a disease of the brain affecting movement
- risk factors for stroke
- tardive dyskinesia, a reaction to some medicines with worm-like movements of the tongue, or other uncontrolled movements of the mouth, tongue, cheeks or jaw which may progress to the arms and legs.
- treatment for cancer
- if you or someone else in your family has a history of blood clots, as medicines like these have been associated with formation of blood clots 

Fluphenazine came into use in 1959. [4] The injectable form is on the World Health Organization's List of Essential Medicines , the most effective and safe medicines needed in a health system . [5] It is available as a generic medication . [1] In the United States the tablets costs between and USD per day for a typical dose. [1] The wholesale cost in the developing world of the long acting form is between and USD per injection as of 2014. [6] It was discontinued in Australia around mid 2017. [7]

An open, multi-centre study was carried out in 69 patients with an acute psychotic episode to assess the efficacy and side-effects of treatment with oral zuclopenthixol dihydrochloride. Patients were treated until the acute episode was considered terminated by the clinician and, although dosage could be adjusted to allow optimum clinical response, the majority received 25 mg zuclopenthixol dihydrochloride 3-times daily throughout the trial period. Assessments were made before and during treatment using the BPRS and CGI rating scales and a check-list of side-effects. The results showed that 55 (80%) patients had a successful response to treatment. Almost half (33) of the patients responded fully to the drug within 3 weeks and by the end of 5-weeks' treatment this had increased to over 70% (49). A further 6 patients responded after 6 to 9 weeks of treatment. The drug was generally well tolerated and the majority of patients had either no side-effects or side-effects which did not overtly affect performance.

Zuclopenthixol decanoate injection

zuclopenthixol decanoate injection

Media:

zuclopenthixol decanoate injectionzuclopenthixol decanoate injectionzuclopenthixol decanoate injectionzuclopenthixol decanoate injectionzuclopenthixol decanoate injection

http://buy-steroids.org